

News Release

Zug, 1 February 2011

Successful Sale of Portfolio Company PharmaSwiss to Valeant


HBM BioVentures' largest private portfolio company PharmaSwiss is acquired by Valeant in an all cash transaction at an equity value of €350 million. The acquisition of PharmaSwiss solidifies Valeant's position as a leading pharmaceutical company in Central and Eastern Europe.

In June 2007, HBM BioVentures invested €54.6 million in PharmaSwiss. After more than two years of interaction with the founders, they were interested in bringing a value-adding investor on board to accelerate the company's expansion. HBM has been an active and very engaged investor at PharmaSwiss with Dr. Andreas Wicki as board member and Dr. Matthias Fehr and Lars-Kristian Bråten as board observers.

One year after HBM BioVentures' investment, Polish Enterprise Fund VI, a private equity fund managed by Enterprise Investors, invested €35 million in PharmaSwiss, enabling HBM BioVentures to increase the valuation of its investment by 36%. Including the appreciation, HBM BioVentures can now record a net profit of €41.9 million, representing a multiple of 1.8x on invested capital.

Dr. Andreas Wicki, CEO of HBM Partners, comments: "HBM was invited to become an investor in PharmaSwiss due to its industry expertise and network, as well as the willingness to be a minority investor in a company controlled by the founders. During the investment period, HBM has been an active contributor at the board level. Furthermore, when requested by management, we have assisted PharmaSwiss in business development, transaction support and by increasing the visibility of the company. This transaction demonstrates the value creation within the HBM portfolio over the past years."

PharmaSwiss has a broad product portfolio in seven therapeutic areas and operations in nineteen countries throughout Central and Eastern Europe. In addition, PharmaSwiss is an existing partner to several large pharmaceutical and biotech companies offering regional expertise in such functions as regulatory, compliance, sales, marketing and distribution. Since HBM's investment in 2007, PharmaSwiss expanded its operations from 12 to 19 countries, doubled the number of employees to more than 750 and increased net revenues from €100 million to €180 million.



About PharmaSwiss S.A.

PharmaSwiss is a privately held multinational specialty pharmaceutical company based in Zug, Switzerland. The company represents major research-based multinationals such as Amgen, Astellas, BMS, Ferring, Ipsen, Lilly, Norgine, Pfizer and Reckitt-Benckiser and also in-licenses and markets its own brands. More information under www.pharmaswiss.com.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information under www.valeant.com

About HBM Partners AG

HBM Partners is among the global leaders in healthcare-focused investing with approximately \$800 million under management. HBM focuses on development-stage, growth and buy-out financings of private companies as well as investments in public companies. HBM Partners advises HBM BioVentures AG (www.hmbioventures.com), HBM BioCapital and further specialized private-equity and public-equity funds. HBM has a complementary team of experienced professionals to source, analyze, execute and exit investments in the pharma/biotech, medical devices and diagnostics industries. We have been an active contributor to value creation in our portfolio companies, generating some 40 trade sales and IPOs since inception. More information under www.hbmpartners.com.